Table 2. Baseline clinical data of patients received ART, Ulaanbaatar, Mongolia, 2010–2017.
| Patient data | Males (n = 146) | Females (n = 34) | Total |
|---|---|---|---|
| Clinical stage (number of patients/percentage) |
|||
| Stage I | 75/45.2 | 26/15.7 | 101/60.8 |
| Stage II | 7/4.2 | 2/1.2 | 9/5.4 |
| Stage III | 16/9.6 | 2/1.2 | 18/10.8 |
| Stage IV | 32/19.3 | 6/3.6 | 38/22.9 |
| CD4 T cell count before initiation of ART (cell/μL) | |||
| Mean ± SD | 317.8 ± 154.1 | 364.5 ± 183.7 | 327.9 ± 161.6 |
| <200 | 34/20.5 | 7/4.2 | 41/24.7 |
| 201–350 | 41/24.7 | 9/5.4 | 50/30.1 |
| 351–500 | 42/25.3 | 12/7.2 | 54/32.5 |
| >500 | 13/7.8 | 8/4.8 | 21/12.7 |
| Baseline viral load (copies/ml)* (number of patients/percentage) |
|||
| High (>100 000) | 37//33.3 | 8/7.2 | 45/40.5 |
| Medium (10 001–100 000) | 30/27.0 | 9/8.1 | 39/35.1 |
| Low (≤ 10 000) | 18/16.2 | 9/8.1 | 27/24.3 |
| ART regimen (number of patients/percentage) |
|||
| 1D scheme: (TDF +3TC+EFV) | 109/65.7 | 26/15.7 | 135/81.3 |
| 1F scheme: (TDF+FTC+EFV) | 21/12.7 | 10/6.0 | 31/18.7 |
| ART guidelines | |||
| WHO 2010 | 8/4.8 | 1/0.6 | 9/5.4 |
| WHO 2013 | 81/48.8 | 23/13.9 | 104/62.7 |
| WHO 2016 | 41/24.7 | 12/7.2 | 53/31.9 |
| Tuberculosis (TB) co-infection† (number of patients/percentage) | |||
| Co-infection | 27/16.3 | 2/1.2 | 29/17.5 |
| TB diagnosed before ART initiation | 9/5.4% | 0 | 9/5.4 |
| TB diagnosed in course of the ART | 18/10.8 | 2/1.2 | 20/12.0 |
Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; EFV, efavirenz; FTC, emtricitabine; SD, standard deviation; TB, tuberculosis; TDF, tenofovir; WHO, World Health Organization
*-baseline viral load was available in 111 patients
†-22 of TB cases identified as pulmonary TB, and 7 of TB cases–as non-pulmonary TB